> University Academic Staffback
A photo of Prof CHAN Tak Mao, Daniel
Prof CHAN Tak Mao, Daniel
Chief of Nephrology Division
Chair Professor, Yu Chiu Kwong Professor in Medicine
MBBS(HK), MRCP(UK), MHKCP, FHKCP, FHKAM (Medicine), MD(HK), FRCP(Edinburgh) , FRCP(Glasgow), FRCP(London), FASN
an email logo
a telephone logo 2255-4542
a fax logo 2816-2863


Professor Tak Mao Daniel Chan is currently Chair Professor, Yu Chiu Kwong Professor in Medicine and Chief of Nephrology Division in the Department of Medicine at the University of Hong Kong. He received his training in Nephrology and Internal Medicine at the University of Hong Kong and Guy's Hospital, London, UK.


Research Profile

T M Chan's research interests include:
  • treatment and immuno-pathogenesis of lupus nephritis
  • management of viral hepatitis in immunosuppressed patients with kidney diseases
The team is internationally recognized for their research output in lupus nephritis. In 2000 he published, in the New England Journal of Medicine, the first randomized controlled trial demonstrating the efficacy and tolerability of mycophenolate mofetil (MMF) in the treatment of severe lupus nephritis. Extended follow-up data from this investigator-initiated study was later published in the J Am Soc Nephrol (2005) and Rheumatology (Oxford) (2013). These results have subsequently been reconfirmed by other investigators and large-scale international multicenter studies, and MMF is now an established first-line standard of care treatment for lupus nephritis. The team has also investigated the potential of calcineurin inhibitors and proliferation signal inhibitors as novel treatments for lupus nephritis.
Their basic research on lupus nephritis pathogenesis focuses on the interaction of anti-dsDNA antibodies with resident renal cells. They discovered that human anti-dsDNA antibodies could bind to annexin II on the surface of mesangial cells. After binding to the cell surface these autoantibodies are internalized and translocated to the cell nucleus, where they mediate downstream inflammatory and fibrotic responses. Translational work is being done to investigate the mechanisms and approaches to intervene progressive renal fibrosis following active lupus nephritis. The results have been published in J Am Soc Nephrol, Arthritis Rheum, and Kidney Int.
The team was among the first in the early 1990s to describe the epidemiology and natural history of hepatitis C infection in dialysis patients and kidney transplant recipients, and is internationally recognized for their work in hepatitis B management in kidney transplant recipients. They showed that pre-emptive antiviral treatment markedly improved the survival of HBsAg+ kidney transplant recipients, and investigated the role of novel antiviral medications. These results have been published in Gastroenterology, Hepatology, Am J Transplant, and Transplantation. He is also an author for related chapters in UpToDate.

Selected Publications

  1. Chan TM*. Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol 2015; 11: 46-61.
  2. Yung S, Ng CYC, Ho SK, Cheung KF, Chan KW, Zhang Q, Chau MKM, Chan TM*. Anti-dsDNA antibody induces soluble fibronectin secretion by proximal renal tubular epithelial cells and downstream increase of TGF-beta1 and collagen synthesis. J Autoimmun 2015; 58:111-122.
  3. Yap DY, Ma MK, Mok MM, Tang CS, Chan TM*. Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. Rheumatology (Oxford) 2013; 52: 480-486.
  4. Lui SL, Yung S, Yim A, Wong KM, Tong KL, Wong KS, Li CS, Au TC, Lo WK, Ho YW, Ng F, Tang C, Chan TM*. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial. Am J Kidney Dis 2012; 60: 966-975.
  5. Yap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM*. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation 2010; 90: 325-330.
  6. Yung S, Cheung KF, Zhang Q, Chan TM*. Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol 2010; 21: 1912-1927.
  7. Yung S, Zhang Q, Zhang CZ, Chan KW, Lui SL, Chan TM*. Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid. Arthritis Rheum 2009; 60: 2071-2082.
  8. Lui SL, Tsang R, Chan KW, Zhang F, Tam S, Yung S, Chan TM*. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. Nephrol Dial Transplant 2008; 23: 2768-2776.
  9. Chan TM*, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
  10. Yung S, Tsang RC, Sun Y, Leung JK, Chan TM*. Effect of human anti-DNA antibodies on proximal renal tubular epithelial cell cytokine expression: implications on tubulointerstitial inflammation in lupus nephritis. J Am Soc Nephrol 2005; 16: 3281-3294.
  11. Chan TM*, Leung JK, Ho SK, Yung S. Mesangial cell-binding anti-DNA antibodies in patients with systemic lupus erythematosus. J Am Soc Nephrol 2002; 13: 1219-1229.
  12. Chan TM*, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.

Research Funding

  • RGC General Research Fund 2015/2016
  • RGC General Research Fund 2014/2015
  • Heath and Medical Research Fund 2014/2015
  • RGC General Research Fund 2013/2014
  • Heath and Medical Research Fund 2013/2014
  • RGC General Research Fund 2012/2013


  1. Kenzo Oshima Award, Asian Pacific Society of Nephrology (2014)
  2. Outstanding Researcher Award, University of Hong Kong (2006)
  3. Sir David Todd Lecture, Hong Kong College of Physicians (2003)
  4. Outstanding Young Researcher Award, University of Hong Kong (1999)

Key Offices

  1. Member of Awards Committee, International Society of Nephrology (2017)
  2. Council Member (Elected), International Society of Nephrology (since 2015)
  3. HKU Senate Member (2013-2016)
  4. Council Member (since 2013) and Vice-President (since 2016), Hong Kong College of Physicians 
  5. Chairman, Central Coordinating Committee (Medicine), Hong Kong Hospital Authority (2012-2015)
  6. Chief of Clinical Service, Department of Medicine, Hong Kong West Cluster Hospitals (2010-2013)
  7. President, Asian Pacific Society of Nephrology (2008-2010)
  8. Associate Dean, HKU LKS Faculty of Medicine (2007-2013)
  9. Nephrology Board Chairman, Hong Kong College of Physicians (2007-2011)
  10. President, Hong Kong Society of Transplantation (1999-2001)
  11. Executive Committee Member, Asian Society of Transplantation (since 1999)